Charles Schwab
GYRE icon

Charles Schwab’s Gyre Therapeutics GYRE Stock Holding History

Charles Schwab’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
184,286
+19,048
+12% +$130K ﹤0.01% 2947
2026
Q1 		$1.15M Sell
165,238
-3,920
-2% -$30.4K ﹤0.01% 2862
2025
Q4 		$1.19M Buy
169,158
+45,772
+37% +$353K ﹤0.01% 2865
2025
Q3 		$920K Sell
123,386
-6,034
-5% -$45.8K ﹤0.01% 2979
2025
Q2 		$951K Buy
129,420
+18,004
+16% +$157K ﹤0.01% 2914
2025
Q1 		$860K Sell
111,416
-3,150
-3% -$34.5K ﹤0.01% 2890
2024
Q4 		$1.39M Buy
114,566
+918
+0.8% +$11.8K ﹤0.01% 2795
2024
Q3 		$1.43M Buy
113,648
+90,557
+392% +$1.17M ﹤0.01% 2805
2024
Q2 		$275K Buy
+23,091
New +$317K ﹤0.01% 3388
2021
Q3 		– Sell
-1,748
Closed -$57K – 3524
2021
Q2 		$57K Sell
1,748
-8,751
-83% -$300K ﹤0.01% 3350
2021
Q1 		$397K Buy
10,499
+3,667
+54% +$168K ﹤0.01% 3157
2020
Q4 		$324K Hold
6,832
– – ﹤0.01% 3129
2020
Q3 		$221K Buy
6,832
+1,054
+18% +$41.3K ﹤0.01% 3150
2020
Q2 		$255K Buy
+5,778
New +$271K ﹤0.01% 3115
2019
Q2 		– Sell
-3,709
Closed -$226K – 3239
2019
Q1 		$226K Buy
3,709
+762
+26% +$49K ﹤0.01% 3001
2018
Q4 		$175K Hold
2,947
– – ﹤0.01% 3035
2018
Q3 		$239K Sell
2,947
-443
-13% -$35.1K ﹤0.01% 3049
2018
Q2 		$297K Buy
+3,390
New +$595K ﹤0.01% 2967
2014
Q2 		– Sell
-47
Closed -$177K – 3110
2014
Q1 		$177K Hold
47
– – ﹤0.01% 2974
2013
Q4 		$154K Hold
47
– – ﹤0.01% 3011
2013
Q3 		$206K Hold
47
– – ﹤0.01% 2908
2013
Q2 		$162K Buy
+47
New +$179K ﹤0.01% 2975

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Charles Schwab's GYRE Position: Q2 2026 in Review

Charles Schwab increased its Gyre Therapeutics (GYRE) stake by 12% in Q2 2026, buying an estimated $130K and bringing the position to 184,286 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #2947.

Charles Schwab first reported a position in GYRE in Q2 2013 and has held it in 22 quarters since. The position peaked at $1.43M in Q3 2024. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Charles Schwab held 184,286 shares of Gyre Therapeutics worth $1.21M as of Q2 2026.
  • Charles Schwab bought 19,048 Gyre Therapeutics shares in Q2 2026, an estimated $130K.
  • Gyre Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2947 holding.
  • Charles Schwab first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 22 quarters since.
  • Charles Schwab's Gyre Therapeutics position peaked at $1.43M in Q3 2024.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.